American Society of Hematology

The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.


Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.

Research Programs and Awards

Explore programs offered by ASH to support clinical and scientific hematology research

Hematology Research Agenda

ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community

  • Born to Friends

    Dr. Moss reviews the often-raised question of how we select a donor for a patient who needs a stem cell transplant and the three main options, which include an HLA-matched unrelated donor (URD), umbilical cord blood transplantation, or a haploidentical donor (HD).

  • MRD Detection Testing to Study Clonal Selection and Drug Resistance

    Dr. O'Donnell and Dr. Raje look at a study that attempts to understand the biology of clonal plasma cells in low levels or MRD states after induction therapy, which can lead to a better understanding of chemoresistance and more effective therapies for MM.

  • Novel Role for Iron Transport in Immune Cell Function

    Dr. Coetzer reviews a study that looks at the molecular defect in a subset of CID patients and resulting enhanced expression of TfR1 on lymphocytes, which has clinical relevance as it could be a useful diagnostic tool.

  • Acute Myeloid Leukemia Minimal Residual Disease Comes of Age

    Dr. George and Dr. Chabot-Richards discuss a study that shows the different roles of NPM1 mutation in risk stratification and MRD monitoring in AML.

View all Diffusion articles
  • Medicare’s Inpatient Proposed Rule and What it Means for Hematology

    The Centers for Medicare and Medicaid Services (CMS) released the annual set of proposals governing payments for services provided to patients admitted to the hospital, commonly referred to as the hospital inpatient prospective payment system (IPPS). ASH explores how this will affect hematologists.

  • ASH Pleads for Payment Innovation in Rare Diseases Such As Sickle Cell Disease

    As part of the American Society of Hematology’s (ASH) multifaceted initiative to address the burden of sickle cell disease, ASH is in the process of working with stakeholders to improve access to care for individuals with sickle cell disease.  Included in this effort is

  • Medicare Proposes Radical Experiment in Drug Payment Policy

    On March 8, 2016, the Center for Medicare and Medicaid Services (CMS) proposed a new experiment in payment rates for physician-administered drugs such as chemotherapy. This plan would change the current formula for drug payment so that payments for expensive drugs are reduced in certain areas of the country. In a second phase, CMS would be able to adopt certain tools to further adjust pricing for drugs.

  • ASH Submits Comments to NHLBI on its Draft Strategic Research Priorities

    ASH submitted comments to the National Heart, Lung and Blood Institute (NHLBI) on its recently released draft strategic research priorities that will inform the Institute’s policy and funding decisions for the next several years. ASH’s comments were developed based on the ASH Agenda for Hematology Research and input from members of the ASH Committee on Scientific Affairs and ASH Scientific Committees.

View all policy news
back to top